Foot infections and their progression are one of the most common and severe complications of diabetes mellitus. In the UK, hospitalization for diabetic patients with foot disorders is greater than all other diabetic complications combined. In the US foot infections in diabetic patients are the leading cause of lower-extremity amputations. In Germany, it has been reported that 72% of non-traumatic lower-extremity amputations are attributable to diabetes.
In most reported series, about a third of diabetic patients who present with foot infections were found to have evidence of osteomyelitis. In nearly all studies of diabetic foot osteomyelitis, there are a number of pathogens involved, the most common being Staphylococcus aureus, followed by other aerobic gram-positive cocci and various aerobic gram-negative bacilli.
Neuropathy, poor perfusion and non‐compliance make diabetic foot infections some of the most difficult to treat, and a primary excision or amputation often leads to secondary and subsequent amputations, reducing quality of life for patients. CERAMENT G and/or CERAMENT V can help in the management of these patients by offering bone remodeling that helps support bone/limb sparing surgery and reduces the risk of amputation, complete dead space management and a high local concentration of antibiotic, irrespective of vascular perfusion profile that reduces the risk of (re)infection. Both products are also radiopaque and injectable through a 16G needle, making them ideal for cases where access is difficult.